Ignite Creation Date:
2024-05-06 @ 3:47 PM
Last Modification Date:
2024-10-26 @ 1:57 PM
Study NCT ID:
NCT04755738
Status:
NOT_YET_RECRUITING
Last Update Posted:
2021-09-05
First Post:
2021-02-07
Brief Title:
Almonertinib Plus Microwave Ablation in Advanced Non-small Cell Lung Cancer
Sponsor:
Qianfoshan Hospital
Organization:
Qianfoshan Hospital
Study Overview
Official Title:
Almonertinib Plus Microwave Ablation Versus Almonertinib in Previously UntreatedAdvanced Non-small Cell Lung Cancer a RandomizedControlledPhase II Clinical Trial
Status:
NOT_YET_RECRUITING
Status Verified Date:
2021-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
MWA
Brief Summary:
Almonertinib as a third-generation EGFR-TKI has been used for the treatment of advanced non small cell lung cancer How to improve the progression free survival in advance was a challenge Our previous study showed that first-line EGFR-TKIs plus microwave ablation had PFS survival advantage versus EGFR-TKIs alone So we conducted this prospective study to verify the efficacy and safety of the combination in a randomized controlled phase II clinical trial
Detailed Description:
Almonertinib as a third-generation EGFR-TKI has been used for the treatment of advanced non small cell lung cancer How to improve the progression free survival in advance was a challenge Our previous study showed that first-line EGFR-TKIs plus microwave ablation had PFS survival advantage versus EGFR-TKIs alone So we conducted this prospective study to verify the efficacy and safety of the combination in a randomized controlled phase II clinical trial Patients were assigned into two groupsIn the experiment group patients were treated with both Almonertinib and microwave ablation In the control group patients were treated with Almonertinib alone The primary end point was progression free survival Second endpoints included overall survival and safety
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None